What if we could reach a future where viral infections are no longer a concern?
It turns out that we can neutralize viruses by putting them into molecular cages. At capsitec, we work on developing this approach into a versatile and adaptable platform for treating viral diseases.
We harness the power of DNA origami nanofabrication and AI-supported molecular design to make our antiviral drugs. Our vision also extends to making more powerful gene delivery vectors and other applications in the future. We are convinced our technology will help addressing the unmet needs of patients and healthcare providers worldwide, contributing to a healthier future.
Introducing the virus trap: A quantum leap in treating viral diseases
Nearly 95% of the more than 200 known viral diseases cannot be treated with medication, and vaccinations are only available for a small number of viruses. Capsitec's innovative, programmable antiviral drug platform has the potential to make a significant impact on this global health challenge.
The virus trap is a revolutionary solution that deactivates viruses by encapsulating them in nano-engineered shells. Our platform can be easily adapted to various viruses and combined with a wide range of virus-binding molecules, offering a broad-spectrum, highly adaptable treatment of acute infections and pre-exposure prophylaxis.
The power of DNA origami nanofabrication
Capsitec's core technology, DNA origami nanofabrication and AI-enabled molecular design, enables us to create programmable, customizable structures at the nanoscale. These structures can be adapted to a wide range of applications, from antiviral therapeutics like our virus trap platform, to gene delivery vectors and vaccines.
We envision a future where DNA origami nanotechnology plays a crucial role in the development of novel therapeutic and diagnostic solutions, improving global health and paving the way for groundbreaking advancements in biotechnology. Capsitec is dedicated to making this vision a reality by continuously innovating and expanding the applications of our core technology.
Capsitec was founded in 2021 and is a spin-off of Technical University of Munich, Germany. Capsitec is operated by a team of experts in DNA nano-engineering, biophysics, virology, and business. With the goal of transforming medical therapy, capsitec leverages the potential of DNA origami nanofabrication, starting with the virus trap for treating and preventing viral infections.
Capsitec is committed to maintaining the highest standards of scientific rigor, quality, and safety in the development of our products. We collaborate with leading researchers and industry partners to ensure that our solutions meet the needs of patients and contribute to the advancement of healthcare worldwide.